A 10-year follow-up study of patients with high-risk bladder cancer shows that mitomycin C (MMC) and bacillus Calmette-Guérin (BCG) have similar effects on disease progression, need for subsequent treatment, and survival.
Contrary to what is commonly thought, the risk of having a positive repeat prostate biopsy is no lower for men with a fluctuating PSA level than it is for those with a steady or steadily increasing PSA level.
Photoselective vaporization of the prostate (PVP) for BPH provides outcomes similar to those of transurethral resection of the prostate (TURP).
Adding the alpha blocker doxazosin to standard treatment may help clear distal ureteral stones, according to researchers in Tashkent, Uzbekistan.
Sorafenib treatment doubles progression-free survival in patients with advanced renal cell carcinoma, regardless of whether they have received prior cytokine therapy.
Botulinum toxin type A (BTX-A) injections may be a promising treatment for BPH patients with urinary retention who are not candidates for surgery.
Dangerous medication errors are most likely to occur in surgical settings, according to a pharmaceutical watchdog.
Hospital-based physicians are doing a poor job of communicating with their primary-care providers (PCPs) when patients are discharged, according to a recent meta-analysis.
Dr. Y, age 57, is an experienced general urologist who practices at a university hospital in the Northeast.
Bladder cancer is projected to be the fourth most common cancer diagnosed in 2007 and the eighth most common cause of cancer-specific death in men, according to the American Cancer Society. Approximately 70% of bladder tumors present as non-muscle invasive (NMI) disease and 10%-20% will progress to muscle invasion.
